Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.40 |
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924650 | 0.93 | PTGS2 (0.47) | PDE4DPDE4APDE4BPDE4CPTGS2 | |
| SCHEMBL2932029 | 0.91 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPTGS2 | |
| SCHEMBL2927419 | 0.91 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CPTGS2 | |
| SCHEMBL2926103 | 0.90 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL2931748 | 0.89 | PIK3CA (0.43) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL6529696 | 0.88 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2926125 | 0.87 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2931338 | 0.84 | GAA (0.44) | PTGS2POLBEGFRPTGS1KMT2A | |
| SCHEMBL2925608 | 0.82 | PDE4D (0.53) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL6532215 | 0.81 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | claimed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | claimed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | claimed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | claimed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | disclosed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | disclosed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | PDE4A, PDE4B, PDE3B | PDE4D 5/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.